select search filters
briefings
roundups & rapid reactions
Fiona fox's blog

expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma

Scientist reacts to abstract presented at EORTC-NCI-AACR 2026* about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma.

Prof Shivan Sivakumar, Professor of Translational Oncology, University of Birmingham, said:

“These are very encouraging results in a disease where progress has historically been difficult to achieve. The combination of daraxonrasib with chemotherapy has demonstrated an impressive response rate of approximately 61%, with patients remaining free from disease progression for a median of nearly 13 months. These outcomes compare favourably with what we have historically seen using chemotherapy alone.

“What is particularly exciting is the potential to move beyond chemotherapy as the mainstay of treatment for pancreatic cancer. By targeting RAS, a fundamental driver of the vast majority of pancreatic cancers, we may be entering an era where molecularly targeted therapies can meaningfully improve outcomes for patients.

“However, we must interpret these findings carefully. This is a relatively small, early-phase study involving 61 patients, without a randomised control group. Comparisons with historical chemotherapy results are therefore not definitive, and we do not yet know whether these promising results will translate into longer overall survival.

“The ongoing international phase III RASolute 303 trial will be critical in determining whether this combination genuinely improves survival compared with standard chemotherapy. If these findings are confirmed, this could represent one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years.”

* ‘Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC)’ by W.Park et al. was presented at the ENA 2026 cancer meeting in Barcelona.

Declared interests

 

For all other experts, no reply to our request for DOIs was received.

in this section

filter RoundUps by year

search by tag